Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Chief Technical Officer steps down from his role at Impero A/S

Company Announcement No. 14-2023 | Changes in management Copenhagen, November 30, 2023 Chief Technical Officer, Allan Lykke Christensen, has decided to step down from his position at Impero A/S by the end of February 2024, as he will pursue new challenges outside Impero. “On behalf of the Board and Impero’s management team, I want to thank Allan for his contribution to the development of Impero. Allan has taken great pride in developing a stronger product team and has contributed to the work of professionalizing the entire organization. Allan took part in listing Impero on Nasdaq

Nokian Tyres plc: Proposals by the Shareholders' Nomination Board to the 2024 Annual General Meeting

Nokian Tyres plc Stock Exchange Release November 30, 2023 at 10:30 a.m. EET Nokian Tyres’ Shareholders' Nomination Board has submitted to Nokian Tyres’ Board of Directors its proposals for the 2024 Annual General Meeting. The Nomination Board proposes that the Board consists of nine members, the Chair and the Deputy Chair included, and that the persons below be elected to the Board of Directors for a term ending at the end of the 2025 Annual General Meeting.  The following persons are proposed to be re-elected:   Susanne Hahn Jukka Hienonen Markus Korsten Christopher

Sensys Gatso Australia receives contract extension of maintenance services for traffic safety systems from the state of Victoria, worth SEK 21 million

Sensys Gatso Group, a global leader in traffic safety solutions, through its subsidiary Sensys Gatso Australia, has received an order to the value of AUD 3 million, corresponding to SEK 21 million to extend the TRaaS maintenance of existing systems until the end of 2024 from the Victorian Government.Traffic Enforcement as a Service (TRaaS) is a critical part of the Sensys Gatso Australia portfolio. This TRaaS order includes the maintenance & support of vehicle monitoring systems at selected intersection & highway sites in the State of Victoria. This order extends the current maintenance and

Scandinavian ChemoTech thanks for the cooperation with its IR consultant who leaves the management team

After more than a year of collaboration, the company and the IR consultant, Jonathan Furelid, have mutually decided to end the collaboration as a result of changing needs for the company regarding its communication. Jonathan thus leaves the management team as of December 31.ChemoTech has initiated the recruitment of a marketing and communications manager to develop the work of increasing the awareness of the Company's unique cancer technology, TSE (Tumor Specific Electroporation) in both Human and Animal Care. "We thank Jonathan for his efforts and wish him continued success in his work",

Sitowise Group Plc issues 33,394 own shares in a directed issue relating to the acquisition of Positive Impact Finland Oy

Sitowise Group Plc                        Changes in company's own shares                          30 November 2023 at 10.15 a.m. EET The Board of Directors of Sitowise Group Plc (“Sitowise”) has decided on 30 November 2023, by virtue of the authorization granted by the annual general meeting on 25 April 2023, to issue 33,394 own shares (the "Share") held by Sitowise in a directed share issue. The number of Shares to be subscribed for in the share issue (the “Share Issue”) corresponds to approximately 0.09 per cent of shares in Sitowise. The Share Issue relates to an acquisition of

Nilar International AB (publ) files for bankruptcy

INSIDER INFORMATION: The Board of Directors of Nilar International AB (publ) ("Nilar" or the "Company") has today decided to file for bankruptcy. The bankruptcy application will be submitted today, November 30, 2023, to the Attunda district court.In line with what the Board of Directors communicated on November 29, 2023, the Board's decision is based on the Company's strained and urgent liquidity needs in both the short and long term, where a solution has not been able to materialize. For more information, please contact:Gunnar Wieslander, chairman of the board Nilar International AB (

Medius to release first AI workmate for the Accounts Payable Industry

Medius , a leading provider of AP Automation and Spend Management solutions, has today revealed its plans for the first AI-powered workmate for the Accounts Payable Automation (APA) industry that delivers a three-pronged innovation strategy in the way invoices are processed.Code named Medius “Agent”, it is designed to help people that approve invoices by delivering useful information about an invoice such as the approval path, discounting opportunities and links to the last five invoices from the vendor. Pre-defined prompts for popular invoice processing queries

AddSecure Group-Clifford Group deal nominated for Dutch M&A Awards in Best Deal Mid-Market category

The prestigious recognition not only highlights the success and impact of the transaction, but also demonstrates that AddSecure executes successful deals that create value for stakeholders and customers alike.On September 18, 2023, AddSecure Group , a leading European provider of secure IoT connectivity and end-to-end solutions, acquired Clifford Group , a leading multi-brand telematics company in the Benelux, to strengthen their market position and expand their service offerings. Now the AddSecure Group - Clifford Group deal has

Read original

Klimator AB (publ) Interim report 3, July – September 2023

Third quarter July 1 – September 30, 2023 Group · Operating income amounted to SEK 5,720K (SEK 4,018K) · Operating profit amounted to SEK -4,565K (SEK -7,109K) · Net profit after income taxes amounted to SEK -4,560K (SEK -7,357K) · Net profit per share after income taxes amounted to SEK -0.15 (SEK -0.47) (Amounts within parentheses refer to the corresponding figures for the same period the prior year) The first nine months January 1 – September 30, 2023 Group · Operating revenue amounted to SEK 18,571K (13,543K). · Operating profit amounted to SEK -16,189K (

Metsä Group’s Kuura textile fibre gained important recognition in sustainability matters

Kuura textile fibre, which is made out of softwood pulp from the Äänekoski bioproduct mill, received a ‘Green Shirt’ rating based on the evaluation arranged by not-for-profit environmental organisation Canopy. Their annual Hot Button Ranking is a well-established tool used in the global textile and fashion industries to assess the sustainability of wood-based textile fibres. The ‘Green Shirt’ rating, awarded to Kuura for the third consecutive year, requires a risk-free, transparent supply chain, and traceable raw materials, among others. Leading brand owners, in terms of environmental

ZINZINO AB (PUBL): Zinzino changes Certified Adviser to Carnegie Investment Bank AB (publ)

Zinzino announces today that it is changing Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Zinzino has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the service as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on 30 November 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser for the company. For more information please contact :Fredrik Nielsen CFO Zinzino +46 707 900 174, email: fredrik.nielsen@zinzino.com Images for free publication:

Interim report Q3 2023

Growing demand for our solutions reflects the need for increased digitalization in health- and social care. The Nordic regions and municipalities need to invest more in IT than they have done historically. Cambio has the products and services to bridge the technical gap that the regions and municipalities face, and to enable tomorrow’s health- and social care. Together with our customers, we contribute to a better and healthier society.Revenue in the third quarter amounted to 256.4 MSEK, representing a growth of 28.8% Q3, July - September January - September 20232023 ·

SSAB at COP28: Ambition and speed must increase

SSAB representatives will participate in more than 20 seminars and round tables during the United Nations Climate Change Conference, COP28, in Dubai. Our key message is that we have the technology to get rid of fossil emissions from steelmaking – now we need policymakers to create the enabling framework for a faster roll-out. Photo: SSAB CTO Martin Pei and fossil-free steel bar. This is the third year that SSAB is joining the annual climate change conference as part of Business Sweden’s delegation. As leader of the green transition in the steel industry, SSAB is committed to

Metsä Group’s Kuura[®] textile fibre gained important recognition in sustainability matters

Kuura textile fibre, which is made from Metsä Group’s softwood pulp, received a ‘Green Shirt’ rating based on the evaluation arranged by not-for-profit environmental organisation Canopy. Their annual Hot Button Ranking is a well-established tool used in the global textile and fashion industries to assess the sustainability of wood-based textile fibres.Espoo, Finland (30th November 2023) Metsä Group’s Kuura textile fibre has achieved high scores based on the Hot Button Ranking  evaluation arranged by the Canadian not-for-profit environmental organisation

Lundbeck R&D Event to showcase innovative pipeline

H. Lundbeck A/S (Lundbeck) is hosting an R&D Event in London today, providing analysts and investors with an update on the progress of its R&D transformation.Today, Lundbeck is hosting an investor R&D Event in London, offering insights into the company’s commitment to leveraging its transformed R&D pipeline for future growth.   The event will feature Lundbeck's CEO Charl van Zyl, Head of R&D Johan Luthman, and other R&D leaders. Lundbeck experienced significant R&D milestones in 2023, securing two FDA approvals, eight key headline results, a phase II proof of concept with a novel

Prostatype Genomics AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

Prostatype Genomics AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Prostatype Genomics has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

Misen Energy AB (publ) changes liquidity provider and Certified Adviser to Carnegie Investment Bank AB (publ)

Misen Energy AB (publ) announces today that it is changing liquidity provider and Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Misen Energy AB (publ) has terminated the assignment regarding liquidity guarantee with Erik Penser Bank AB and has appointed Carnegie Investment Bank AB (publ) as the new liquidity provider for the company's shares that are listed on the Nasdaq First North Growth Market in Stockholm. The change of liquidity provider is in accordance with Nasdaq Stockholm's regulations regarding liquidity providers. In its role as liquidity

Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ)

Biosergen AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).Biosergen AB has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

Interim Report January–September 2023

ChromoGenics increases order intake and continues to lower costsQ3 2023 (July–September) · Net sales amounted to SEK 1.6 (3.5) million, a decrease of SEK 1.9 million compared to the corresponding quarter in 2022. · Operating costs excluding depreciation and amortization and financial expenses amount to SEK 12.2 (22.0) million in Q3 2023 and correspond to a decrease in costs of SEK 9.7 million or 44 percent. · Earnings before tax, depreciation/amortization and financial items (EBITDA) improved in the quarter by SEK 2.5 million and amount to SEK -9.2 (-11.7) million. · Cash flow

Beijer Ref presents new financial targets

Beijer Ref’s board has decided on new financial targets. The new targets are based on continued good opportunities for growth as well as increased clarity towards the market and investors. Christopher Norbye, CEO Beijer Ref, comments: "We see that the market has developed positively and the company is in a good position. The existing platform is strong and we continue to build for further growth.” New financial targets for the next 5 years: New target: Sales growth of 10-15% annually Old target: Grow at a higher rate than the market New target: EBITA margin of 10-12%

Positive tax restructuring in Beijer Ref's US operations

During the year, a tax restructuring took place in the Beijer Ref US operations, which has resulted in an increase in the tax base of the US operations by an additional approximately MUSD 235. Together with the now expanded tax base, the payable tax in the US operations is expected to be positively impacted by approximately MUSD 200 over a 15-year period.The lower payable tax will be recognized on an ongoing basis as deferred tax liability, which is why profit in the coming years will not be affected. The tax restructuring also means that a currently recognized deferred tax liability of

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the initiation of a Phase 2 clinical study to evaluate setanaxib in Alport syndrome.Calliditas is a company focused on developing and commercializing novel treatments in rare diseases with significant unmet medical needs. This randomized, double-blind, placebo-controlled study will evaluate setanaxib in approximately 20 patients with a genetic diagnosis of Alport syndrome and significant proteinuria despite treatment with a renin-angiotensin system (RAS) blocker. The duration of treatment is

There are no items matching the current filter
There are no more items matching the current filter
Back to top